Imipramine and Desipramine, Serum or Plasma
Also known as: DESIP/IMIP
Use
This test is used to optimize dosing and monitor patient adherence to imipramine and desipramine therapy. It helps ensure therapeutic levels are maintained and reduces the risk of toxicity. Therapeutic drug monitoring can assist in assessing patient compliance, managing side effects, and making informed dosage adjustments to maintain safe and effective levels of the drugs in serum or plasma.
Special Instructions
Timing of specimen collection should be a predose (trough) draw at steady-state concentration to ensure accurate measurement of drug levels.
Limitations
Whole blood, gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution) are unacceptable specimens for this test due to the potential for inaccurate results. Additionally, the test is not approved by the FDA; it was developed by the laboratory and its performance characteristics were determined at ARUP Laboratories. Toxic concentrations can cause anticholinergic effects, drowsiness, and cardiac abnormalities, underscoring the importance of careful monitoring.
New York Approved
Methodology
Mass Spectrometry
Biomarkers
LOINC Codes
- 3531-1
- 3690-5
- 9627-1
Result Turnaround Time
2-8 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
1 mL
Minimum Volume
0.5 mL
Container
Plain red tube, Lavender (K2 or K3EDTA), or pink (K2EDTA) tube
Collection Instructions
Predose (trough) draw at steady-state concentration. Separate serum or plasma from cells within 2 hours of collection and transfer to ARUP standard transport tube.
Storage Instructions
Refrigerated
Causes for Rejection
Whole blood, gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 5 days |
| Refrigerated | 2 weeks |
| Frozen | 6 months |